DOSE — Rapid Dose Therapeutics Balance Sheet
0.000.00%
Last trade - 00:00
- CA$24.76m
- CA$27.35m
- CA$0.72m
- 39
- 12
- 85
- 42
2019 February 28th | 2020 February 29th | 2021 February 28th | 2022 February 28th | 2023 February 28th | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 3.49 | 0.003 | 0.07 | 0.034 | 0.028 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 0.286 | 0.111 | 0.255 | 0.183 | 0.146 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 4.1 | 0.414 | 0.798 | 0.614 | 0.42 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 1.68 | 3.88 | 3.03 | 2.45 | 1.83 |
Total Assets | 5.78 | 4.29 | 3.83 | 3.07 | 2.25 |
Accounts Payable | |||||
Payable / Accrued | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 1.96 | 3.48 | 4.74 | 2.45 | 4.7 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Liabilities | 1.96 | 4.44 | 5.41 | 2.82 | 4.92 |
Common Stock | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | 3.83 | -0.148 | -1.58 | 0.252 | -2.67 |
Total Liabilities & Shareholders' Equity | 5.78 | 4.29 | 3.83 | 3.07 | 2.25 |
Total Common Shares Outstanding |